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also causes, and is related to, the development of 
atherosclerosis and/or atherosclerotic plaques in 
the vascular system.
 The atherosclerosis and cardiovascular diseases 
are appears to be the primary cause of early death 
in RA and other autoimmune diseases, as compared 
to the normal population. Myocardial infarction, 
ischemic heart disease, heart failure, sudden death, 
and stroke have become the primary causes for the 
increasing cardiovascular mortality.4-6
 As a result, comprehensive assessment and 
treatment of the traditional and non-traditional 
cardiovascular risk factors is an important part of 
the routine management of RA patients.6 The proper 
identification and stratification of RA patients 
with a high risk and the immediate treatment is an 
important part in the management of rheumatoid 
diseases such as RA.
Methods
This is a cross-sectional research which was 
performed at Dr. Cipto Mangunkusumo National 
General Hospital (RSCM) in Jakarta from October 
2012 – March 2013. The subject of this research 
was patients with RA who came for treatment 
at the Rheumatology clinic at RSCM, Jakarta; 
fulfilled the inclusion criteria; and did not fulfill the 
exclusion criteria. The inclusion criteria employed 
in this study were RA patients with aged minimum 
16 years old when the diagnosis was made, fulfilled 
the RA criteria of EULAR/ACR 2010, and were 
willing to participate in this study and have signed 
the informed consent form. The exclusion criteria 
were subjects who were pregnant or lactating; 
those who suffered from a malignant disease; has a 
history of consuming biologic agents; has a history 
of myocardial infarction, stroke, or peripheral 
arterial disease.
 The collected data included: the length of 
time since RA diagnosis, patient age, the presence 
of risk factors such as hypertension, smoking, 
type 2 diabetes mellitus, obesity, dyslipidemia, 
serum anti-CCP antibody levels, antioxidized - 
LDL antibody levels, hand and foot radiology 
examination to assess RA severity (Sharp ve Heijde 
Score), Carotid USG examination to assess CIMT 
and atherosclerotic plaque. The analyzed variables 
were categorized into groups of yes and no, and 
associated with the presence of atherosclerosis and 
atherosclerotic plaques.
Abstract
Background: Atherosclerosis and cardiovascular 
diseases have been known as the cause of increasing 
mortality among rheumatoid arthritis (RA) patients. 
Carotid intima media thickness (CIMT) measurement 
by ultrasound has been used as surrogate marker of 
atherosclerosis and cardiovascular disease. 
Methods: A cross sectional study of 86 RA patients 
fulfills EULAR/ACR 2010 critera for RA was conducted to 
study proportion and predictor factors of atherosclerosis 
and atherosclerosis plaque in rheumatoid arthritis 
patients. 
Results: Atherosclerosis and plaque was found in 
47,7%		and	29	%	of	patients.	Age	≥	40	yo,	hypertension	
and	duration	of	illness	≥	24	mo	were	associated	
with atherosclerosis in multivariate logistic regression 
analysis with OR 10.70 (95% CI: 2.93-39.10), 4.99 
(95% CI: 1.15-21.61) and 3.66 (95% CI: 1.11-11.99) 
respectively. Whereas hypertension, presence of anti-
CCP	antibody	and	age	≥	40	yo,	were	associated	with	
plaque formation with OR 3.96 (95% CI: 1.15-13.57), 
3.20 (95% CI: 1.11-9.24) and 3.61 (95% CI: 1.03-12.63) 
respectively. 
Conclusions: Age	≥	40	yo,	hypertension	and	
duration	of	illness	≥	24	mo	was	the	predictors	of	
atherosclerosis, while hypertension, presence of anti-
CCP	antibody	and	age	≥	40	yo	was	the	predictors	of	
atherosclerosis plaque.
Key words: atherosclerosis, intima media thickness, 
predictor, rheumatoid arthritis, ultrasonography.
Introduction
Rheumatoid Arthritis (RA) is a rheumatoid 
disease marked by the presence of autoimmunity 
and systemic chronic inflammation. This chronic 
disease, which occurs in 0.5 – 1.0% of population, 
causes progressive polyarthritis inflammation and 
joints damage.1 Other than the increase in morbidity 
associated with the joint damage, RA patients 
are also associated with increased mortality 
when compared to the normal population.2,3 The 
mechanism by which increase cardiovascular 
mortality occurs in RA patients is a complex one. The 
increase in cardiovascular morbidity and mortality 
in RA patients may not be completely attributed 
to the traditional risk factors such as obesity, 
dyslipidemia, diabetes mellitus, hypertension, and 
smoking.4,5 This chronic inflammatory condition 
in RA causes not only synovitis of the joints, but 
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 Hypertension was defined using the JNC VII;7 DM II based 
on The Indonesian Society of Endocrinology (PERKENI) 
2011 criteria for diagnosis;8 smoking was based on the CDC 
definition;9 dyslipidemia based on NCEP/ATP III;10 obesity 
was defined as BMI ≥ 25kg/m2;11serum anti-CCP antibody 
levels and antioxidized-LDL antibody levels were considered 
positive if the results were > 25 U/mL dan > 30 U/mL, 
respectively.
 USG examination was performed by a professional and full 
trained radiologist to determine the presence of atherosclerosis 
and atherosclerotic plaques using the standardized method 
with B-mode Philips® Sonos 5500 USG and a high frequency 
linear transducer (>7 MHz). Atherosclerosis was defined by 
CIMT ≥ 1,0 mmat the common carotid artery, and/or the 
internal carotid artery, and/or carotid bulb on the left and/or 
right side.12-15 Atherosclerotic plaque was determined by the 
presence of one of the following during the atherosclerosis 
examination: abnormal CIMT(≥1,5mm), abnormal shape 
(bulging into the lumen, loss of alignment with the arterial 
wall), presence of abnormal wall texture (echo brighter that 
the surrounding border). 12-15
Results
In this research, we included 120 RA patients. From the 120 
subjects, we have 93 subjects. Three patients were dropped 
out due to refuse undergone blood test, USG, and other 
radiological examination. Further, 4 others patients also 
refused to undergo the USG and radiology examination after 
undergoing the blood test. Finally, 86 subjects participated 
in this study, with complete medical history, laboratory 
examination, carotid USG and radiology. From the 86 subjects 
who were analyzed, atherosclerosis was found in 41 subjects 
(47.7%) and atherosclerotic plaque in 25 subjects (29%). The 
subjects comprised of eight males (9.3%) and 78 females 
(90.7%). Other subject characteristics can be seen in Table 1. 
The carotid artery thickness can be seen in Table 2.
Table	1.	Subject Demographics
Variable
Total No. of 
Subjects 
N = 86
Atherosclerosis Atherosclerotic Plaque
No Yes No Yes
N = 45 N = 41 N =61 N = 25
Gender
Male (%) 8 (9,3) 4 (4,65) 4 (4,65) 4 (4,6) 4 (4,6)
Female (%) 78 (90,7) 41 (47,67) 37 (43,0) 57 (66,3) 21 (24,4)
Age (years)* 49,5 (20-70) 38 (20-61) 56 (28-70) 43(20-70) 56 (28-69)
Duration of disease (months)* 25,5 (2-233) 17 (2-133) 36 (3-233) 23 (2-145) 28 (3-233)
Treatment (%)
Methyl prednisolon 63 (73,3)
   MTX 54 (62,8)
   SSZ 17 (19,8)
   MTX+SSZ 15 (17,4)
Dosage*
Methyl pred(mg/day) 4 (0-16) 4 (0-16) 4 (0-16) 4 (2-16) 4 (2-16)
MTX (mg/week) 11,25 (SD 3,4) 10 (7,5-17,5) 10 (7,5-20) 10 (7,5-20) 12,5 (7,5-20)
SSZ (g/day) 1 (1-2) 1 (1-2) 1 (1-2) 1,28 (SD 0,45) 1,11 (SD 0,33)
DAS 28 Score* 3,7 (2,09-6,47) 3,62(2,09-6,03) 3,70(2,58-6,47) 3,7 (2,09-6,03) 3,5 (2,70-6,47)
Remission (<2,6) 5 (5,8)
      Mild (≤3,2) 17 (19,8)
Moderate (>3,2≤5,1) 56 (65,1)
Severe (>5,1) 8 (9,3)
BMI (kg/m2) 23,9 (SD 4,41) 23,68 (SD 4,66) 24,05 (SD 4,18) 23,7 (SD 4,53) 24,30(SD 4,17)
ESR(mm/1hour)* 45 (5-135) 48 (5-135) 40 (10-110) 49 (10-135) 33 (5-99)
CRP (%)
Negative 41 (47,7) 20 (44,4) 21 (51,2) 28 (45,9) 13 (52,0)
Positive 45 (52,3) 25 (55,6) 20 (48,8) 33 (54,1) 12 (48,0)
Rheumatoid Factor (%)
Negative 31 (36,0) 18 (0,4) 13 (31,7) 22 (36,1) 9 (36,0)
Positive 55 (64,0) 27 (0,6) 28 (68,3) 39 (63,9) 16 (64,0)
Anti-CCP Antibody (%)
Negative 53 (61,6) 28 (62,2) 25 (61,0) 41 (67,2) 12 (48,0)
Positive 33 (38,4) 17 (37,8) 16 (39,0) 20 (32,8) 13 (52,0)
Anti ox-LDL (%)
Negative 22 (25,6) 10 (22,2) 12 (29,3) 14 (23,7) 8 (32,0)
Positive 62 (72,1) 33 (71,1) 29 (70,7) 45 (76,3) 17 (68,0)
Hypertension (%)
No 70 (81,4) 41 (91,1) 29 (33,72) 53 (86,9) 17 (68,0)
Yes 16 (18,6) 4 (8,9) 12 (13,95) 8 (13,1) 8 (32,0)
Type 2DM (%)
No 82 (95,35) 45 (100) 37 (90,2) 60 (98,4) 22 (88,0)
Yes 4 (4,65) 0 (0,0) 4 (9,8) 1 (1,6) 3 (12,0)
Dyslipidemia (%)
No 58 (67,4) 32 (71,1) 26 (63,4) 42 (68,9) 16 (64,0)
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Yes 28 (32,6) 13 (28,9) 15 (36,6) 19 (31,1) 9 (36,0)
Smoking (%)
No 85 (98,8) 45 (100) 40 (97,6) 61 (100) 24 (96,0)
Yes 1 (1,2) 0 (0,0) 1 (2,4) 0 (0,0) 1 (4,0)
Obesity (%)
No 49 (57,0) 27 (0,6) 22 (53,7) 37 (60,7) 12 (48,0)
Yes 37 (43,0) 18 (0,4) 19 (46,3) 24 (39,3) 13 (52,0)
Sharp van Heijde Score*
Total 32 (0-355) 28(0-355) 40(2-121) 31 (0-355) 40 (2-107)
Hand 20 (0-271) 17 (0-271) 23 (1-97) 19 (0-271) 23 (1-95)
Foot 10 (0-84) 9 (0 - 84) 11 (0 - 24) 9 (0- 84) 11 (0-21)
* Median (minimum-maximum), SD: Standard Devia tion 
Table 2. Carotid Artery CIMT
Artery CIMT (min-max) mm
Common Carotid Artery 0,683 (0,39-1,94)
Internal Carotid Artery 0,705 (0,45-2,04)
Carotid Bulb 0,850 (0,38-4,34)
Bivariate analysis showed that the predicting factors associated 
with the presence of atherosclerosis in RA were patients aged 
≥ 40 years, duration of illness ≥ 24 months, hypertension and 
type 2DM. The predicting factors associated with the presence 
of atherosclerotic plaque in RA patients were age ≥ 40 years; 
duration of illness ≥ 24 months; hypertension;type 2DM; and 
the anti CCP antibody status. Smoking was not included in the 
bivariate analysis or the multivariate analysis because only 1 
subject was a smoker. 
 Variables in the bivariate analysis with p value < 0.25 were 
age ≥ 40 years, illness duration ≥ 24 months, hypertension,and 
type 2DM were included in the multivariate analysis for 
atherosclerosis. The variables age ≥ 40 years, illness duration 
≥ 24 months, hypertension, type 2DM, and the anti CCP 
antibody status were included in the multivariate analysis 
for atherosclerotic plaques. The multivariate analysis of the 
variables can be seen in Table 3 and 4. 
Table 3. Atherosclerosis Multivariate Analysis
Variable OR (95%CI) p
Age > 40 years 10,70 (2,93-39,10) <0,001
Hypertension 4,99 (1,15-21,61) 0,031
Duration of illness ≥ 24 
months 3,66 (1,11-11,99) 0,032
Table 4. Atherosclerotic Plaque Multivariate Analysis
Variable OR (95%cI) p
Hypertension 3,96 (1,15-13,57) 0,029
Anti CCP Antibody 3,20 (1,11-9,24) 0,031
Age ≥ 40 years 3,61 (1,03-12,63) 0,044
Multivariate analysis revealed that the variables with statistical 
significance for the occurrence of atherosclerosis, in order, 
were age ≥ 40 years, hypertension, and illness duration ≥ 24 
months; whereas for atherosclerotic plaque, in order, were 
hypertension, Anti CCP antibody status, and age ≥ 40 years.
 To predict the probability of atherosclerosis and 
atherosclerotic plaque, multivariate analysis provided the 
regression coefficient for each variable. Based on the analysis, 
the probability for atherosclerosis and atherosclerotic plaques 
were each calculated using the specific model equation based 
on the presence of specific variables in the individual. 
 The probability model equation obtained was:
For atherosclerosis, the equation for probability was = P = 1/ 
1+ e –y
e = constant, 2.7
y = the equation obtained from multivariate analysis using 
logistic regression, for atherosclerosis y = -(-3,068 + 2,370 
[age ≥ 40 years] + 1,296 [duration of illness ≥24 months] + 
1,608 [hypertension]),
Therefore P =       
    1
1+ e-(-3,068 + 2,370 [age ≥ 40 years] + 1,296 [duration of illness ≥24 months] + 1,608 [hypertension])
For atherosclerotic plaque, the probability =
    1
1+ e-(-2,634 + 1,285 [age ≥ 40 years] + 1,376 [hypertension] + 1,164 [anti-CCP status])
To simplify and allow easy use of the probability prediction 
for atherosclerosis and atherosclerotic plaque in daily practice, 
thus a scoring system was constructed. The use of this scoring 
system allows easier identification and stratification of RA 
patients with a high cardiovascular risk.
 The prediction score for atherosclerosis and atherosclerotic 
plaque for each variable was made based on the rounding of 
the result from the division of the regression coefficient with 
the standard error (SE) from each predicting variable. Thus, 
the score for each variable (Table 5 and 6), are obtained. 
Table 5. Atherosclerosis Prediction Score
Variable B SE B/SE Score Rounded To
Age ≥ 40 years 2,370 0,661 3,585 1,67 2
Duration of illness ≥24 months 1,296 0,606 2,139 1,00 1
Hypertension 1,608 0,747 2,152 1,01 1
Table 6. Atherosclerotic Plaque Prediction Score
Variable B SE B/SE Score Rounded To
Age ≥ 40 years 1,285 0,638 2,014 1,00 1
Anti-CCP Status 1,164 0,541 2,152 1,07 1
Hypertension 1,376 0,629 2,186 1,09 1
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Based on the available score for each variable, with the 
logistic regression, a total score can be obtained, thus 
allowing measurement of the probability for atherosclerosis 
and atherosclerotic plaque based on the total score for every 
individual.
 For atherosclerosis, the probability, based on the total 
score, can be calculation using the following equation:
    1
1+ e -(-3,077 + 1,248 [total score])
From this equation, the probability for each total score can be 
calculated (Table 7).
Table 7. The Probability of Atherosclerosis Based on the Total Score
Total Score Probability of Atherosclerosis
0 4,5 %
1 14 %
2 36 %
3 66 %
4 76%
For atherosclerotic plaque, the probability can be calculated 
based on the total score by the following equation:
         1
1+ e-(-2,638 + 1,265[total score]) 
From this equation the probability for each score can be 
calculated (Table 8).
Table 8. Probability of Atherosclerotic Plaque Based on the Total 
Score
Total Score Probability of Atherosclerotic Plaque
0 7 %
1 20 %
2 47 %
3 76 %
The prediction score for atherosclerosis and atherosclerotic 
plaque have been tested for the quality or performance 
by calibration test (Hosmer-Lemeshow Test) and for 
discrimination ability by observing the result of the under 
receiver operating characteristic curve[AUC].In the 
atherosclerotic prediction score the Hosmer Lemeshow got a 
result of p = 0.794(p > 0.05) which indicates that the precision 
is good. Similarly, the discrimination ability to differentiate 
patients who will suffer atherosclerosis from those who will 
not have atherosclerosis was also good (AUC = 0.800; 95% 
CI 0.707 - 0.892).For the prediction of atherosclerotic plaque 
occurrence, the Hosmer Lemeshow score p = 0.696(p > 0.05) 
which indicates that the prediction model has good precision. 
The discrimination ability of the atherosclerotic plaque 
prediction score based on the AUC is moderate (AUC = 0.719; 
95% CI 0.599-0.839).
 The second internal validation of the scoring system was 
done using the Bootstrapping method. Following validation, 
the Hosmer Lemeshow test gave a p value of 0.838 and 0.956 
for atherosclerosis and atherosclerotic plaque, respectively. 
The Hosmer-Lameshow p value > 0.05 after the Bootstrapping 
method was done to show that the two prediction scores were 
internally validated ina proper manner. 
Discussion
This research involved 86 subjects, eight (9.3%) males and 
78 females (90.7%). However, this observation varies from 
previous research which show that the proportion of males to 
females is 3 : 4. This may be caused by the difference in the 
population, location of research, and inclusion and exclusion 
criteria. Further, the median age of subjects in this research 
is 49.5 years. The youngest subject being 20 years old and 
the oldest 70 yeasr old. Similar results are reported in other 
studies which show that RA is most commonly found in the 
4th – 5th decades. Furthermore, the duration of illness in the 
subjects of this study ranged from 2 months till 9.7 years.
 Disease activity, as assessed by the DAS-28LED Score, 
was moderate in majority of the patients (65%). High disease 
activity was found in 9% of the subjects, low activity in 20% 
of the subjects, and only 6% were in remission. The small 
proportion of patients in remission and a low average weekly 
MTX dose (11.25 mg), and the limited types of DMARDs 
available appear to be correlated. This may be attributed to the 
limited DMARD options available at the medical formularium 
and the lack of funds among the patients. Moreover, this small 
percentage of patients in remission necessitates additional 
consideration and further research.
 Atherosclerosis (CIMT ≥ 1.0mm) and atherosclerotic 
plaque were found in 41 subjects (47.7%) and 25 subjects 
(29%), respectively. The cut-off for CIMT of ≥ 1.0mm was 
used in this study is considered to increase the risk for a 
cardiovascular event in the future. This cut-off is also the 
level used by the Radiology Department at FKUI/RSCM 
Jakarta where USG examination and other research are 
conducted.12,14,15
 The proportion of subjects with atherosclerosis and 
atherosclerotic plaques were different compared to previous 
studies. This may be attributed to the difference in definition, 
cut-off values, population, examination methods, location, 
and measuring instruments used. Different academic centers 
and research groups have different cut-off values, methods and 
examination approaches.16
 Gender was not identified as a significant risk factors with 
the occurrence of atherosclerosis by bivariate and multivariate 
analysis. In this study, there were only eight male subjects 
(9.3%) with a proportion of 1 : 10 compared to the number 
of female subjects, lower than the proportions mentioned 
in the literature. Currently, no research has ever reported 
the association of a specific gender with the occurrence of 
atherosclerosis in RA patients.
 In this research, age ≥ 40 years and duration of illness ≥ 
24 months are significantly associated with the occurrence 
of atherosclerosis. Through logistic regression analysis on 
atherosclerosis, the OR for age ≥ 40 years and duration of 
illness ≥ 24 months were 10.7 (CI 95% 2.93 – 39.1; p < 0.001) 
and 3.66 (CI 95% 1.11 – 11.99; p = 0.032), respectively. In the 
analysis for atherosclerotic plaque, a significant association 
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was found with age ≥ 40 years, the OR being 3.61 (CI 95% 
1.03 – 12.63; p = 0.044).
 Age and duration of illness were associated with CIMT 
in this research, similar to the findings in other studies.17-21 
Atherosclerosis is a chronic, continuous process which begins 
at a young age and grows with age. CIMT in the healthy 
population usually increase with age.22 Age is a primary 
factor that determines the extent of atherosclerosis. Longer an 
individual suffers from RA, more severe is the atherosclerosis 
compared to patients of the same age but earlier in the course 
of the disease. This finding is similar to that reported by 
Rincon et al.23
 Hypertension is a traditional predicting factor, significantly 
associated with atherosclerosis and atherosclerotic plaque 
formation, OR 4.99 (CI 95% 1.15 – 21.16; p = 0.031) and 
3.96 (CI 95% 1.15 – 13.57; p = 0.029), respectively. However 
a significant association between hypertension and CIMT was 
not found in the study by Gonzales-Juanatey.20 On the other 
hand, Roman MJ showed that in RA patients, atherosclerosis 
is associated with age, hypertension status, and use of TNF 
alpha inhibitors.19 In this study, hypertension was a significant 
risk factor for atherosclerosis and atherosclerotic plaque 
formation that can be changed and treated.
 Type 2 Diabetes Mellitus was not a predicting factor for the 
occurrence of atherosclerosis and atherosclerotic plaques in 
this research. Similarly, MJ Roman, YB Park, and Ahmed also 
reported the same results.17,19,21 Different population, genetics, 
background, RA diagnostic criteria, and also atherosclerosis 
and atherosclerosis plaque diagnostic critera may cause 
discrepancy between our result and the others study result.
 Dyslipidemia isn’t a predicting factor of atherosclerosis 
and atherosclerosis plaque in this study. Similarly with 
YB Park and MJ Roman study.17,19 A complex relationship 
between dyslipidemia, inflammation, and RA may be the 
reason underlying the lack of a significant association between 
dyslipidemia and atherosclerosis in this research, other than 
the difference in population, RA diagnostic criteria, and 
method of atherosclerosis examination.
 Smoking is a traditional predicting factor for the 
occurrence of atherosclerosis. In addition, it causes more 
severe joint damage in RA. However, in this research smoking 
was not significantly associated with atherosclerosis. There 
is a need for more subjects who have a smoking habit to 
correctly identify the role of smoking as the predicting factor 
for atherosclerosis and atherosclerotic plaques. The study by 
MJ Roman also reported smoking as a significant predicting 
factor for atherosclerotic plaques.19
 The median BMI in this research was 23.9 kg/m2(SE 4.4). 
Obesity (BMI ≥ 25 kg/m2) was not significantly associated 
with the occurrence of atherosclerosis in this research. This 
finding is in accordance with the study by Kremer et al.24 
Different from the common population, RA patients with low 
BMI (< 20 kg/m2) had a higher risk for cardiovascular death 
compared to non-RA patients with normal BMI. Moreover, 
in RA, BMI has a paradoxical effect on mortality. Patients 
with BMI ≥ 30 had lower mortality rate (1.7 deaths / 100 
individuals/year) compared to patients with BMI < 20 (10.5 
deaths/ 100 individuals/year).25  More severe the inflammation 
appears to be correlated with more severe cachexia that is 
correlated with increase morbidity rate.
 Anti-CCP antibodies were found in 33 subjects (38.4%) 
in this study. The presence of anti-CCP antibodies was not 
significantly correlated with the occurrence of atherosclerosis, 
but the association with atherosclerotic plaque was significant, 
with OR 3.2 (CI 95% 1.1 – 9.2; p = 0.029). The significant 
association between anti-CCP with atherosclerotic plaque 
formation was also reported by Lopez FJL, et al where RA 
patients with positive anti-CCP antibodies (> 25 unit/mL) 
had higher myocardial ischemia (6.5% vs. 2.6%; OR 2.56, CI 
95% 1.17 – 5.56) and mortality rates (11.2% vs. 6.8%; OR 
1.72, CI 95% 1.01 – 2.91) compared to RA patients without 
anti-CCP antibodies. They demonstrated an association 
between anti-CCP antibodies of patients with RA and the 
presence of coronary heart disease independent of traditional 
cardiovascular risk factors. Their report revealed an 
underlying autoimmune inflammatory disorder affecting not 
only the development of articular RA manifestations, but also 
the cardiovascular comorbidity of RA.26
 Another research in the Rheumatology Clinic at RSCM 
by Yuliani and Manuaba reported the prevalence of anti-CCP 
antibodies at 60.4% (91 subjects) and 56% (46 subjects), 
respectively.27,28 This difference may be attributed to the 
difference in population, RA diagnostic criteria, and method 
of examination.
 The prevalence of antioxidized-LDL antibodies in this 
research was 61.6% (53 out of 86 subjects). A significant 
association between anti oxidized-LDL antibodies with 
atherosclerosis or atherosclerotic plaque formation was not 
found. In contrast, Ahmed et al, reported that patient age, 
CRP, and Ox-LDL antibodies were independent risk factors 
of atherosclerosis.21 This difference may be caused by the 
variation in atherosclerosis and atherosclerotic plaque criteria 
and definition, as well as the method of examination.
 Radiology examination score in a cross sectional research 
describes the severity of joint damage occurring in RA at a 
specific point of time. In this research, a median Sharp van 
Heidje score of 28 and 40 for patients with and without 
atherosclerosis, respectively; and 31 and 40 for patients 
with and without atherosclerotic plaques, respectively. 
The differences were not statistically significant. The 
complex interaction between inflammation, joint damage, 
and occurrence of atherosclerosis may underlie this result. 
Similarly, Gonzales-Juanatey et al, did not find a significant 
association between joint damage (using the Larsen score) 
with carotid CIMT and carotid plaques.29
 Multivariate analysis by logistic regression testing 
allowed the construction of a scoring system which calculates 
the probability of atherosclerosis and atherosclerotic plaque 
formation for each score. The prediction score of 0, 1, 2, 3, and 
4 are associated with a  4%, 14%, 36%, and 87% probability 
of developing atherosclerosis, respectively. On the other hand, 
the score 0, 1, 2, and 3 are associated with a 7%, 20%, 47%, 
and 76% probability of developing an atherosclerotic plaque, 
respectively.
 Based on the prediction scores for atherosclerosis and 
atherosclerotic plaque formation, the researchers categorized 
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the prediction scores into low, moderate, and high. For 
the atherosclerosis prediction score 0 – is low risk with a 
probability of up to 14% for the occurrence of atherosclerosis 
(CIMT ≥ 1.0mm). A score of 2 with a 36% probability of 
developing atherosclerosis is categorized as moderate risk. 
Further, a score of 3 – 4 are categorized as high risk, with a 
66% to 97% risk of developing atherosclerosis. For patients 
with moderate risk, the researchers recommend CIMT 
examination to determine the presence of thickening of the 
tunica intima. For high risk patients, primary prevention of 
atherosclerosis complications and cardiovascular events, 
without CIMT examination is recommended (Table 11).
 Similarly, there is the prediction scores for the development 
of atherosclerotic plaques. A score of 0 is considered as low 
risk with a 7% probability of atherosclerotic plaque. A score of 
1 with a 20% probability of atherosclerotic plaque formation 
is considered as moderate risk, and the researchers suggest 
CIMT measurement for these patients. Further, a score of 2 
– 3 is considered as high risk with at least a 47% probability 
of developing atherosclerotic plaques. In patients with high 
risk, primary prevention is recommended without the need for 
CIMT examination (Table 12).
Table 9. Recommendations Based on Atherosclerosis Prediction 
Scores
Score Risk Probability of
Atherosclerosis
Recommendation
0-1 Low 14 % Observation
2 Moderate 36 % CIMT Examination
3-4 High 66 – 87 % Primary Prevention
Table 10. Recommendations Based on Atherosclerotic Plaque 
Prediction Scores
Score Risk Probability of 
Atherosclerotic 
Plaques
Recommendation
0 Low 7 % Observation
1 Moderate 20 % CIMT Examination
2-3 High 47 - 76 % Primary Prevention
Internal validation of this predictive study was conducted 
using the Bootstrapping method in the statistical software, 
SPSS. Following 1000 times of sample repetition, the Hosmer-
Lameshow value for atherosclerosis and atherosclerotic plaque 
formation were 0.838 and 0.956, respectively. Both of the p 
values were > 0.05, thus it may be assumed that the internal 
validation of this research is good, for the prediction factors of 
atherosclerosis and atherosclerotic plaque formation.
 For external validation, a multicenter research must be 
conducted with a similar design on the RA population in a 
different location. The aim of performing a multicenter study is 
to identify the inference and generalization ability of this study 
to RA patients in Indonesia, thus allowing the construction of 
more definite suggestions and recommendations. 
 Currently, to the researchers’ knowledge, this is the first 
study which focuses on identifying the relationship between 
the predicting factors, including the demographic (age and 
duration of illness), clinical (presence of hypertension, 
diabetes mellitus, dyslipidemia, and obesity), laboratory 
(presence of anti-CCP and antioxidized-LDL antibodies), 
and radiology variables (Sharp van Heijde Score) with the 
occurrence of atherosclerosis and atherosclerotic plaques, 
identified by CIMT examination as the surrogate marker, by 
multivariate analysis among the RA population in Indonesia. 
The results of this research, obtained by multivariate analysis, 
may be used as the background for more developed research 
to determine the relationship or association between the 
independent and dependent variables (atherosclerosis and 
atherosclerotic plaques), using this research design which 
is more simple and focused. It is recommended for further 
research to examine and further identify the role of those 
significant factors, and to focus on the relationship between 
hypertension and anti-CCP antibodies with atherosclerosis 
and atherosclerotic plaque formation.
 The results of this study hints on the possible role that 
anti-CCP antibodies, an important and relatively novel 
serology analysis in Indonesia, may play in the formation 
of atherosclerosis and atherosclerotic plaque formation. The 
significant association between the presence of anti-CCP 
antibodies and atherosclerotic plaque formation indicates 
the role of autoimmunity in RA, atherosclerosis, and 
atherosclerotic plaque formation. The results of this research 
serve as evidence to the role anti-CCP antibodies in the 
development of subclinical atherosclerosis and ischemic heart 
disease in RA patients.26,29
 For clinicians who deal with RA patients on a regular 
basis, the results of this research provides a screening and 
stratification tool for RA patients and their probability of 
developing atherosclerosis and atherosclerotic plaques. 
 The cross sectional design of this study does not allow a 
cause-and-effect analysis of the predicting variables and the 
outcomes, atherosclerosis and atherosclerotic plaques. Further 
research with a cohort design is required to clarify the cause 
and effect relationship between the predicting variables with 
atherosclerosis and atherosclerotic plaques.
 Smoking was not analyzed as a variable because only 1 
patient was a smoker. However, smoking has been proven 
and is known to be an important predicting factor of 
atherosclerosis and atherosclerotic plaque formation in the 
non-RA population. The role of smoking as a predicting factor 
could not be analyzed in this study, thus smoking should be 
considered in the generalization and inference of the results 
obtained in this study. The researchers recommend clinical 
judgment, still more important than the scoring system 
constructed from this research.
 Predicting model or scoring system obtained from this 
research does not analyze the duration of hypertension, 
diabetes mellitus, or quantity/length of time of smoking 
history. This research did not consider the therapy or drugs/
combination of DMARDs or other medications such as 
anti-hypertensives or statins being consumed or have been 
consumed, which may affect the occurrence of atherosclerosis 
and/or atherosclerotic plaques. Ultrasound and radiology 
examinations for atherosclerosis plaque and Sharps van 
Heidje score was done by one examiner respectively for all 
subjects.
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Conclusion
The proportion of atherosclerosis and atherosclerotic plaques 
among RA patients was 47.7% and 29%, respectively. Age ≥ 
40 years, hypertension, and duration of illness ≥ 24 months 
are, in order, significant predicting factors for the development 
of atherosclerosis in RA patients. Hypertension, Anti-CCP 
status, and age ≥ 40 years are, in order, the predicting factors 
for the development of atherosclerotic plaques in RA patients.
Regarding this research, there are several recommendations 
for researchers, clinicians, and policy makers. First, further 
research is required, using a prospective multicenter design with 
more detailed categorization (age; duration of illness; length 
of time since hypertension and diabetes mellitus diagnosis; 
quantity and types of medications being consumed, etc) for 
the external validation and to clarify the relationship between 
the predicting factors and the occurrence atherosclerosis and 
atherosclerotic plaques among RA patients in Indonesia. For 
clinicians and other medical professionals who work with RA 
patients, and the patient’s family members should consider 
patient age, hypertension, duration of RA disease, and anti-
CCP status in the management of RA to reduce mortality due 
to cardiovascular events. For policy makers such hospital 
directors, health ministers, and professional organizations 
such as Indonesian Doctors Association and The Indonesian 
Society of Internal Medicine to consider factors such as patient 
age, hypertension, duration of RA disease, and anti-CCP 
status when constructing the standard operating procedures, 
clinical practice guidelines, or medical treatment guidelines 
for the management of RA, to increase the quality of patient 
treatment; and to allow the optimal, appropriate, and cost-
effective use of resources.
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